Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Otsuka picks up PTSD drug with $700M Transcend buy

 March 27, 2026

BioPharma Dive

The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly paradigm-shifting therapy in psychiatry.

M&A / DealsNeuroscienceRead full story

Post navigation

AstraZeneca lung drug gets ‘surprise’ win in COPD trials →
← Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com